Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 3/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | NT5E | P21589 | 2/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19714524 | 1.00 | YTHDC1 (0.51) | YTHDC1CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL17802577 | 0.89 | YTHDC1 (0.45) | YTHDC1CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL19714683 | 0.89 | CFTR (0.56) | YTHDC1CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL17802573 | 0.89 | CFTR (0.56) | YTHDC1CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL17802575 | 0.89 | YTHDC1 (0.45) | YTHDC1CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL19714621 | 0.86 | YTHDC1 (0.57) | YTHDC1CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL17815588 | 0.86 | YTHDC1 (0.57) | YTHDC1CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL17815676 | 0.80 | CFTR (0.53) | CYP2D6CYP2C9TSHRCYP2C19CDK5 | |
| SCHEMBL19714546 | 0.80 | CFTR (0.53) | CYP2D6CYP2C9TSHRCYP2C19CDK5 | |
| SCHEMBL17815586 | 0.76 | YTHDC1 (0.55) | YTHDC1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414768-B2 | Compounds for treating cystic fibrosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-09-17 | — | — | US | disclosed |
| US-10414768-B2 | Compounds for treating cystic fibrosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-09-17 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| WO-2016087665-A2 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414768-B2 | Compounds for treating cystic fibrosis | CFTR, ABCB11, SLC26A4 | YTHDC1 3944/4885CYP2D6 106/4885CYP2C9 101/4885 |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | CFTR, ABCB11, SLC26A4 | YTHDC1 3944/4885CYP2D6 106/4885CYP2C9 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.